A Study of Loading Doses of Intravenous Bondronat (Ibandronate) in Patients With Breast Cancer and Metastatic Bone Disease.

Inclusion Criteria: * adult patients, \>=18 years of age; * breast cancer; * bone metastases; * mean worst pain score \>=4 during 3 day baseline period; * stable dose of analgesics over a 3 day baseline period; * adequate renal function. Exclusion Criteria: * bisphosphonate treatment within 3 weeks of study enrollment; * a change in antineoplastic treatment within 6 weeks of study enrollment; * bone radiation within 2 weeks of study enrollment; * active infection.